Aurora Cannabis Inc. (ACB) P/E Ratio History
Deep ValueTrading at -1.8x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2018–2025
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, Aurora Cannabis Inc. (ACB) trades at a price-to-earnings ratio of -1.8x, with a stock price of $2.67 and trailing twelve-month earnings per share of $-1.31.
The current P/E is 102% below its 5-year average of 106.4x. Over the past five years, ACB's P/E has ranged from a low of 0.4x to a high of 643.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, ACB trades at a 108% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
Relative to the broader market, ACB trades at a notable discount to the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ACB DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ACB Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ACB P/E vs Peers
Cannabis and cannabinoid product companies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 27.0 | - | +505%Best | |
| $2B | 15.7Lowest | 4.20 | -29% | |
| $448M | 32.9 | 0.98Best | +51% | |
| $67M | 21.5 | - | -77% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ACB Historical P/E Data (2018–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Mar 31 2025 | $4.39 | $0.05 | 87.8x | -17% |
| FY2025 Q3 | - | $4.25 | $0.23 | 18.5x | -83% |
| FY2024 Q3 | Dec 31 2023 | $4.76 | $12.27 | 0.4x | -100% |
| FY2024 Q2 | Sep 30 2023 | $5.85 | $10.80 | 0.5x | -99% |
| FY2024 Q1 | Jun 30 2023 | $5.35 | $9.30 | 0.6x | -99% |
| FY2019 Q2 | Sep 30 2018 | $1152.00 | $27.69 | 41.6x | -61% |
| FY2019 Q1 | Jun 30 2018 | $848.39 | $14.45 | 58.7x | -45% |
| FY2018 Q3 | Dec 31 2017 | $915.60 | $1.42 | 643.0x | +504% |
Average P/E for displayed period: 106.4x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ACB — Frequently Asked Questions
Quick answers to the most common questions about buying ACB stock.
What is ACB's P/E ratio?
Aurora Cannabis Inc. (ACB) trailing twelve-month P/E ratio is -1.8x, based on TTM diluted EPS of $-1.31. The 5-year average P/E is 106.4x and the historical range spans 0.4x to 643.0x.
Is ACB stock overvalued or undervalued?
ACB trades at -1.8x P/E, below its 5-year average of 106.4x. At the 0th percentile of its historical range (0.4x–643.0x), the stock is priced at a discount to its own history.
Is ACB stock expensive?
No, ACB is not expensive on a historical basis. The current P/E of -1.8x is below the 5-year average of 106.4x and sits at the 0th percentile of its valuation range.
What is ACB's historical P/E range?
Over the past 5 years, ACB's P/E ratio has ranged from 0.4x to 643.0x, with a median of 41.6x and an average of 106.4x. The current P/E of -1.8x places the stock at the 0th percentile of this range. Full historical data spans 2018–2025.
How does ACB's P/E compare to the S&P 500?
ACB trades at -1.8x P/E versus the S&P 500 median of 25.9x. The 107% discount to the market suggests lower growth expectations or perceived higher risk.
How does ACB's valuation compare to Healthcare peers?
Aurora Cannabis Inc. P/E of -1.8x compares to the Healthcare sector median of 23.4x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ACB's PEG ratio?
ACB PEG ratio is N/A, based on a P/E of -1.8x and EPS growth of -7643.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ACB's earnings yield?
ACB earnings yield is N/A, the inverse of its -1.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.